News from ibio, inc

Oct 31, 2013, 13:44 ET

SCD-iBIO to Honor Purdue's Dr. George Tsao for Contributions to Industrial Biotechnology

The Society for the Commercial Development of Industrial Biotechnology (SCD-iBIO), an affiliate of the Society of Chemical Manufacturers and...

Oct 28, 2013, 08:10 ET
iBio, Inc. logo.  (PRNewsFoto/iBio, Inc.)

iBio Resolves NYSE MKT Listing Standards Deficiency

iBio, Inc. ( NYSE MKT: IBIO ) today announced receipt on October 25, 2013 of notice from NYSE Regulation that iBio had resolved all...

Oct 15, 2013, 18:41 ET

iBio, Inc. Announces Temporary Reduction in Exercise Price of Certain Warrants

 iBio, Inc. (NYSE MKT: IBIO) today announced that it is providing holders of its warrants to purchase common stock issued on January 13, 2012...

Oct 14, 2013, 08:20 ET
iBio, Inc. logo.  (PRNewsFoto/iBio, Inc.)

iBio, Inc. Receives Notice that NYSE MKT Grants Extension to Regain Compliance with Continued Listing Standards and Corrects Misleading Third-Party Statements

 iBio, Inc. (NYSE MKT: IBIO) today announced that on October 11, 2013, the NYSE MKT (the "Exchange") notified the Company that it accepted the...

Oct 07, 2013, 16:36 ET
iBio, Inc. logo.  (PRNewsFoto/iBio, Inc.)

iBio Reports on Filing of Annual Report and Subsequent Event Amendment of Collaboration with Fraunhofer

 iBio, Inc. (NYSE MKT: IBIO), a biotechnology company focused on commercializing its proprietary transformative recombinant platform...

Sep 10, 2013, 14:15 ET

DSM's Marcel Lubben to Keynote SCD-iBIO's Second International Forum

 SCD-iBIO, an industrial biotechnology group associated with the Society of Chemical Manufacturers and Affiliates (SOCMA), today announced that...

Aug 13, 2013, 08:52 ET
iBio, Inc. logo.  (PRNewsFoto/iBio, Inc.)

iBio IP Expanded by New iBioLaunch™ Dual Vector Patent Allowance

 iBio, Inc. (NYSE MKT: IBIO) announced today that the US Patent and Trademark Office has allowed patent application 13/243,796 entitled...

Aug 05, 2013, 08:48 ET
iBio, Inc. logo.  (PRNewsFoto/iBio, Inc.)

iBio Commercial Vaccine IP Expanded by New iBioModulator™ Patent Allowance

iBio, Inc. (NYSE MKT: IBIO) announced today that the US Patent and Trademark Office has allowed patent application 13/445,492 entitled...

Jun 24, 2013, 09:24 ET
iBio, Inc. logo.  (PRNewsFoto/iBio, Inc.)

iBio Pharmaceutical Technology Embraced by the Government of Brazil

iBio, Inc. (NYSE MKT: IBIO) today released the following information, which was contained in the Portuguese language report published on June...

Jun 10, 2013, 07:30 ET
iBio, Inc. logo.  (PRNewsFoto/iBio, Inc.)

iBio Adds Chinese Patent For Anthrax Antibody

 iBio, Inc. (NYSE MKT: IBIO) today announced that its patent covering the composition and production of a human monoclonal antibody for the...

Jun 05, 2013, 07:30 ET
iBio, Inc. logo.  (PRNewsFoto/iBio, Inc.)

iBio, Inc. Receives Notice that NYSE MKT Accepted the Company's Plan to Regain Compliance with Continued Listing Standards

 iBio, Inc. (NYSE MKT: IBIO) today announced that on May 31, 2013, the NYSE MKT (the "Exchange") notified the Company that it accepted the...

May 29, 2013, 07:30 ET
iBio, Inc. logo.  (PRNewsFoto/iBio, Inc.)

iBio Obtains New IP Protection in China

 iBio, Inc. (NYSE MKT: IBIO) today announced that a patent to increase influenza vaccine performance through the use of iBio's proprietary...

May 22, 2013, 07:30 ET
iBio, Inc. logo.  (PRNewsFoto/iBio, Inc.)

iBio Technology Produces Vaccine Candidate for Recently Emerged H7N9 Influenza

PRNewswire – iBio, Inc. (NYSE MKT: IBIO) today announced the production of a vaccine candidate for the newly emerged H7N9 influenza virus by...

Apr 29, 2013, 08:46 ET
iBio, Inc. logo.  (PRNewsFoto/iBio, Inc.)

iBio, Inc. closes $4.2 million public offering and terminates At-the-market offering

iBio, Inc. (NYSE MKT: IBIO) announced today that the Company closed an underwritten public offering of 8,925,000 shares of the Company's common...

Apr 23, 2013, 08:45 ET
iBio, Inc. logo.  (PRNewsFoto/iBio, Inc.)

iBio, Inc. Prices $4.2 Million Public Offering

 iBio, Inc. (NYSE MKT: IBIO) announced today the pricing of an underwritten public offering of 8,925,000 units at $0.48 per unit for...

Apr 22, 2013, 16:02 ET
iBio, Inc. logo.  (PRNewsFoto/iBio, Inc.)

iBio, Inc. Announces Proposed Public Offering

 iBio, Inc. (NYSE MKT: IBIO) today announced that it is offering shares of its common stock and common stock purchase warrants in an...

Apr 22, 2013, 08:30 ET
iBio, Inc. logo.  (PRNewsFoto/iBio, Inc.)

iBio Passes Commercial Technology Transfer Milestone

 iBio, Inc. (NYSE MKT: IBIO) today announced the achievement of a critical technology transfer milestone verified by an independent third...

Apr 22, 2013, 08:00 ET
iBio, Inc. logo.  (PRNewsFoto/iBio, Inc.)

iBio, Inc. receives Notice from NYSE MKT Staff that Company currently is not in compliance with an additional Continued Listing Standard

 iBio, Inc. (NYSE MKT: IBIO) announced today that the Company has received notice from NYSE MKT (the "Exchange") that, based on a review of...

Apr 09, 2013, 07:00 ET
GE alliance awarded contract to design new plant based manufacturing facility in Brazil.  (PRNewsFoto/iBio, Inc.)

GE alliance awarded contract to design new plant-based manufacturing facility in Brazil

 GE Healthcare (NYSE: GE) and iBio, Inc. (NYSE MKT: IBIO), today announced GE Healthcare has signed a contract to design a new plant-based...

Mar 26, 2013, 07:30 ET
iBio, Inc. logo.  (PRNewsFoto/iBio, Inc.)

iBio Selects Proprietary Recombinant C1 Inhibitor for Clinical Development

iBio, Inc. (NYSE MKT: IBIO) today announced the addition of its proprietary iBioLaunch™-produced recombinant C1 esterase inhibitor to the...

Organizations in the News

The organizations with the most activity in PR Newswire's News Room

Research and Markets
Analysts Review
ReportBuyer